Committee Recommends Expanding Sample Size After Interim Analysis Places Study in Protocol-Defined Promising Zone SAN DIEGO, June 1, 2026 /PRNewswire/ — Ansun Biopharma, Inc., a clinical-stage biopharmaceutical company, today announced that its independent Data Monitoring Committee (DMC)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
